Emmanuel Katsanis, MD

Links

I am a Professor of Pediatrics, Medicine, Immunobiology, Pathology and a member of the University of Arizona Cancer Center, Steele Children’s Research Center and the Bio5 Institute. I combine my expertise in the laboratory and the clinical arenas as the Director of the Hematopoietic Cellular Therapy and Transplant Program (adult and pediatric) and Division Chief of Pediatric Hematology/Oncology. I have 30+ years of research experience in the field of tumor and transplant immunology.

Cancer Focus

More recently my work has focused on immunomodulation with bendamustine following haploidentical-BMT. Additionally, my laboratory is studying pre-transplant modulation of host cells by selective agents and their effects on immune reconstitution, graft versus host disease and graft versus tumor effects. I designed and initiated an ongoing phase I/Ib clinical trial in haploidentical bone marrow transplantation based from our published preclinical work.

Research Program Role

Clinical and Translational Oncology Program

Display Name
Emmanuel Katsanis, MD

Publications

Katsanis E, Sapp LN, Reid SC, Reddivalla N, Stea B. 2020. T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies. Front Pediatr. 8:282. doi:10.3389/fped.2020.00282.

Baker FL, Bigley AB, Agha NH, Pedlar CR, O’Connor DP, Bond RA, Bollard CM, Katsanis E, Simpson RJ. 2019. Systemic β-Adrenergic Receptor Activation Augments the Expansion and Anti-Tumor Activity of Vγ9Vδ2 T-Cells. Front Immunol. 10:3082. doi:10.3389/fimmu.2019.03082.

Graff RM, Kunz HE, Agha NH, Baker FL, Laughlin M, Bigley AB, Markofski MM, LaVoy EC, Katsanis E, Bond RA, et al. 2018. β-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. Brain Behav Immun. 74:143–153. doi:10.1016/j.bbi.2018.08.017.

Stokes J, Hoffman EA, Molina MS, Eremija J, Larmonier N, Zeng Y, Katsanis E. 2018 Oct. Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2018.10.009.

Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y. 2018. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 24:2034–2039. doi:10.1016/j.bbmt.2018.06.007.

Zeng Y, Hahn S, Stokes J, Hoffman EA, Schmelz M, Proytcheva M, Chernoff J, Katsanis E. 2017. Pak2 regulates myeloid-derived suppressor cell development in mice. Blood Adv. 1:1923–1933. doi:10.1182/bloodadvances.2017007435.

Stokes J, Hoffman EA, Zeng Y, Larmonier N, Katsanis E. 2016. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation. Br J Haematol. 174:102–16. doi:10.1111/bjh.14034.

Zeng Y, Stokes J, Hahn S, Hoffman E, Katsanis E. 2014. Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD. Bone Marrow Transplant. 49:1076–83. doi:10.1038/bmt.2014.91.

Centuori SM, Trad M, LaCasse CJ, Alizadeh D, Larmonier CB, Hanke NT, Kartchner J, Janikashvili N, Bonnotte B, Larmonier N, et al. 2012. Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol. 92:987–97. doi:10.1189/jlb.0911465.

Emmanuel Katsanis, MD

Links

Cancer Focus

Display NameEmmanuel Katsanis, MD

Publications

Display Name
Emmanuel Katsanis, MD